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Summary A genetically reshaped human IgGI monoclonal antibody (Hu2PLAP) with anti-tumour specificity,
was radiolabelled with Indium-l 1 by chelation with a new macrocyclic compound (DOTA) which allows the
production of stable radioimmunoconjugates for in vivo application. This was used to image seven patients
with malignant disease, of whom two had been previously exposed to mouse monoclonal antibodies and had
developed human anti-mouse antibodies (HAMA). Successful tumour localisation was seen in the four patients
with active disease and antigen positive tumours. No patient showed any antibody responses against
Hu2PLAP, but three out of six patients tested showed an immune response against the macrocycle DOTA.
Reshaped human monoclonal antibodies with anti-tumour specificity may facilitate repeated administrations
of radioactive antibodies, thus allowing new possibilities, both in the diagnosis and treatment of cancer.
It has been previously shown that successful tumour localisa-
tion, and sometimes therapy can be achieved by the use of
radioactively labelled murine monoclonal antibodies (Epene-
tos et al., 1982; Epenetos et al., 1984; Epenetos et al., 1987).
Two major problems, however, have been identified that do
not allow for the full potential of antibodies to be realised.
Firstly, murine antibodies when administered into humans,
often act as immunogens themselves, leading to the develop-
ment of antiglobulin responses (Courtenay-Luck et al., 1988).
This limits further treatment with murine antibodies.
Secondly, conjugation of antibodies with radioisotopes has
often produced unstable radioimmunoconjugates resulting in
the release of radioisotope in vivo; this can reduce the anti-
tumour efficacy of such radioimmunoconjugates and increase
toxicity to normal organs such as bone marrow (Stewart et
al., 1990). The problem of antiglobulin responses should
be reduced or eliminated by the use of human antibodies.
The reshaped human antibody (Hu2PLAP) with anti-tumour
specificity has been constructed by transplanting the hyper-
variable regions otherwise known as complementarity deter-
mining regions (CDRs) of the mouse monoclonal antibody
H17E2 (Travers & Bodmer, 1984) onto human immunoglo-
bulin framework regions (Riechmann et al., 1988; Verhoeyen
et al., 1990). Human IgGl was chosen because, if shown to
target successfully to tumours, it can potentially be used
therapeutically due to its great activity in complement lysis
and cell mediated killing. The problem ofinstability of radio-
immunoconjugates has been overcome for some metallic
radionuclides by the use of a new bifunctional macrocyclic
chelating agent known as DOTA (Moi et al., 1988). DOTA
has been shown in previous in vitro (Moi et al., 1988; Snook
et al., 1990; McCall et al., 1990) and in preclinical (Snook et
al., 1990; McCall et al., 1990; Deshpande et al., 1990) and
clinical (Meares et al., 1990) in vivo studies to result in the
production of stable radioimmunoconjugates. Radioimmuno-
conjugates incorporating DOTA and radiolabelled with
yttrium-90 have been investigated therapeutically in patients
with ovarian cancer (Hird et al., 1990).
Here we describe a study of imaging and pharmacokinetics
of a reshaped human antibody Hu2PLAP-DOTA-"l'In con-
jugate in patients with and without previous human anti-
mouse globulin responses, and compared its kinetics with the
original murine H17E2. This is the first report of in vivo
targetting using a fully reshaped human monoclonal anti-
body with anti-tumour specificity and stably radiolabelled
using a novel macrocycle for clinical application.
Patients, materials and methods
Patients
The seven patients were aged between 36 and 65 years, and
had undergone prior surgery and chemotherapy for their
malignant disease. One patient (K.S.) was in complete remis-
sion at the time of the antibody scan. Two patients (M.F.
and J.E.) had raised serum levels of human antimouse anti-
body prior to receiving Hu2PLAP antibody. This followed
previous exposure to murine antibodies; M.F. had received
HMFG1-DTPA-YY intraperitoneally as an attempted form
of treatment of extensive intraperitoneal disease. J.E. had
previously undergone H17E2-DOTA-'"In radioimmunoscin-
tigraphy and had, also developed anti-DOTA antibody res-
ponses.
Humanised monoclonal antibodies
Transfectoma cells (cells transfected with a certain gene)
were prepared containing the genes for Hu2PLAP (Verhoyen
et al., 1990). Purified Hu2PLAP was prepared from trans-
fectoma supernatants derived from hollow fibre cell cul-
ture using protein-A and PLAP affinity chromatographies.
Immunoreactivity of this material was greater than 80% as
judged by analytical PLAP affinity chromatography.
H17E2 is a murine IgGl which reacts with human placen-
tal alkaline phosphatase (Travers & Bodmer, 1984). Immuno-
histologically it reacts strongly against a wide range of
neoplasms including those of the testis, ovary and cervix, and
negatively against healthy tissues except term placenta
(Epenetos et al., 1984). It has been shown to localise in vivo
to tumour lesions in patients with ovarian, testicular and
other cancers (Epenetos et al., 1985).
Radiolabelling
The antibody Hu2PLAP was coupled via 2-iminothiolane
(2IT) to bromoacetamido-benzyl-DOTA (2-p-nitrobenzyl-
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1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid)
(Snook et al., 1990). DOTA coupled antibody was subse-
quently labelled with "'In (Amersham Int. UK) to a specific
activity of 2 mCi mg-'.
ELISAfor anti-DOTA, anti-mouse andanti-human antibodies
Ninety-six well, round bottomed microtiter plates were coat-
ed overnight with 37°C with 2ttgml-' HSA (Human Serum
Albumin), HSA-2IT and HSA-21T-DOTA in bicarbonate
buffer, pH 9.6. Control wells were treated with bicarbonate
buffer alone in order to determine non-specific binding of
serum Ig. Then serial dilutions in PBS/0.05% Tween (10-
fold) of each patient's serum were applied on the plates and
incubated at 37°C for 2 h in a humidified chamber. After
three washes in PBS/0.05% Tween the plates were incubated
with a species-specific second reagent (sheep anti-human Ig,
1:1000 dilution in PBS/0.05% Tween), at 37°C for 1 h. Then
the plates were washed three times in PBS/0.05% Tween and
incubated in the dark at room temperature with 100 il of
ABTS substrate, and the absorbance at 405 nm was deter-
mined by a multiscan plate reader.
In the above described ELISA method each patient's
serum was tested against: (i) no antigen to determine any
non-specific binding on the plates, (ii) HSA in order to
determine if there is a pre-existing response against HSA, (iii)
HSA-2IT, in order to test for the development of antibodies
against the 21T linker and (iv) HSA-2IT-DOTA, in order to
test the response against the macrocycle DOTA. Some con-
trol wells were incubated with PBS/Tween instead of serum
and then received only the second layer reagent in order to
determine any cross reactivity between the above antigens
and the second layer reagent. The background binding of
serum on the plates was always between 0-20% and there
were no detectable antibodies against HSA and HSA-21T.
Most of the patients had <5% background binding, but two
of these had 15-20%, a rare finding, thought to be due to
high immunoglobulin serum content.
The ELISA methods used for measuring anti-mouse
(Courtenay-Luck et al., 1986) and anti-human (Courtenay-
Luck et al., 1987) antibody responses have been described
previously. The development of antibodies to Hu2PLAP was
estimated in two different aspects: (i) Anti-idiotypic anti-
bodies; and (ii) Anti-constant region antibodies.
(i) The development of anti-idiotypic (anti-variable region
antibodies) was estimated after coating 96 well round
bottomed ELISA plates with 5 tLgml-' in bicarbonate buffer,
pH 9.6, of H17E2, AUA1, HMFG1 which are of the same
isotype IgGl, but with different binding specificities. The
assay was performed as described in the ELISA for anti-
DOTA antibodies. Development of significantly higher res-
ponse against H17E2 having identical binding sites with
Hu2PLAP (because this is grafted with the CDRs of murine
H17E2 antibody), than AUA1 and HMFG1 would suggest
the development of anti-variable region antibodies.
(ii) The development of anti-constant region antibodies was
tested as previously described (Courtenay-Luck et al., 1986)
provided that the Hu2PLAP antibody has the same degree of
glycosylation (on the Fc portion) as the other murine mono-
clonal antibodies (H17E2, HMFG1, AUA1). We assumed
this to be the case as it also produced by a NSO myeloma
cell lines (transfectoma).
Imaging
220-833 jg Hu2PLAP-DOTA-In"' (specific activity 2 mCi
mg-') was administered intravenously to each patient.
Images of the whole body and abdomen were obtained
immediately after injection and again at 48 and 96 h later.
Pharmacokinetics
Blood samples were obtained immediately after injection, at
1 h, and then at the time of subsequent scans.
Urine was collected continuously from the time of the
injection to the time of the last scan.
Results
Toxicity
No toxicity was seen. The procedure was well tolerated by all
the patients.
Images
Tumour localisation was seen in four patients (M.F., M.D.,
N.N., P.H.) with active disease (Figure 1). Three patients
(K.S., J.E., S.L.) showed no evidence of tumour localisation
(Table I). Of these three patients, one patient (K.S.) had no
evidence of disease clinically, or on CT scan and her serum
CA 125 was within normal limits. One patient (J.E.) cleared
the antibody rapidly due to pre-existing anti-DOTA anti-
bodies, and no images could be obtained. The other patient
(S.L.) had antigen negative tumour.
Antibody responses
Anti-DOTA antibodies were found in the sera of three out of
six patients tested following administration of the antibody.
Two patients (M.F., J.E.) had human anti-mouse antibodies
(HAMA) due to prior exposure to mouse monoclonal anti-
bodies. One of these (J.E.) also had anti-DOTA antibodies
due to prior exposure to a murine antibody conjugated to
DOTA. A further two patients developed anti-DOTA anti-
Figure 1 The whole body antibody scans using Hu2PLAP-
DOTA-In-ll in a patient with extensive ovarian carcinoma.
This woman had high levels of human anti mouse antibody prior
to administration of the humanised H17E2. The images have
been taken immediately and 2 days post injection. Arrows point
to tumour areas.USE OF RADIOACTIVE RESHAPED HUMAN MONOCLONAL ANTIBODIES 913
bodies following administration of Hu2PLAP-DOTA-"'In
(S.L., M.D.). None of the controls or the patients had any
pre-existing anti-DOTA antibodies. No antibody responses
against the human monoclonal antibody Hu2PLAP were
seen (Table I).
It was not possible to quantitate polyclonal serum res-
ponses. IgM antibodies are of lower affinity than IgG and
therefore any attempt to purify the anti-DOTA or HAMA
responses, with antigen (HSA-DOTA or murine Ig) coated
Sepharose CNBr beads, would be more likely to lead to
isolation of IgG.
Pharmacokinetics ofHu2PLAP-DOTA-"'In
Patients M.F. and J.E. had pre-existing HAMA responses
(Table I), hence, excluding these patients, Hu2PLAP-DOTA-
"'In cleared from blood with a mean T12P= 73.1 ± 30.2 h
(n = 5); this is significantly longer (P<0.05, Student's t-test)
than that of H17E2-DOTA- "'In T1/2B = 27.2 ± 5.9 (n = 3)
(Hird, unpublished data). At 96 h the mean cumulative urine
excretion for these patients was 11 + 8% (n = 4) compared to
14 ± 5% (n = 3) for the murine equivalent (Hird, unpub-
lished data). Patient J.E. had only 27% of the administered
activity remaining in her blood at 1 h post-injection, the
remainder cleared with a T1/2P= 39 h giving a cumulative
urine excretion (at 96 h) of 31%. For patient M.F. these
values were T1/2P = 47 h and 66% respectively.
Discussion
This study shows that the genetically reshaped human IgGl
Hu2PLAP monoclonal antibody with anti-tumour specificity,
when conjugated with the macrocycle DOTA and radio-
labelled with Indium-l1, can successfully localise to tumours
in patients with antigen positive malignant disease such as
ovarian cancer. No toxicity was observed. It was of interest
that the reshaped human IgGI antibody had a longer half
life than the original murine H17E2 antibody. However, this
was considerably shorter than normal human IgGl antibody.
It is possible, that following chelation with the macrocycle
DOTA and labelling with "'In, the antibody does not behave
any more as normal human IgGI. Furthermore, Hu2PLAP is
produced in a mouse cell line and is probably glycosylated
differently than it would be in a 'normal' human cell.
None of the patients produced any serologically detect-
able anti-Hu2PLAP or other anti-human globulin responses,
even though two patients had a high human anti-mouse
antibody response due to prior exposure to murine antibody.
Two patients, however, developed an anti-immunoconjugate
response, but this was found to be directed against the
macrocycle DOTA rather than against the reshaped human
antibody. The immunogenicity of the DOTA and other simi-
lar compounds is currently being investigated in order to
design new and non-immunogenic chelates (Kosmas et al.,
submitted).
The long-term advantages of reshaped human IgGl
Hu2PLAP or other antibody used both for imaging and
therapy will be assessed only in larger trials, but this data
provide considerable encouragement to this approach.
The work in preparing DOTA was supported by NIH Grant
Number: Ca 16861.
TableI DetailsofimagingofthepatientswhoreceivedHu2PLAP-DOTA-In-1 11,theirdiseasestatusatthetimeofinjection,
and their immune responses against murine (HAMA), reshaped Hu2PLAP antibodies and the macrocycle DOTA
Pre-existing Dose of Responses
Patient's responses Hu2PLAP Tumour
number Abbrev. Disease Status DOTA HAMA (Asg) a Hu2PLAP a DOTA localisation
1 M.F. OvCa Stage III Active - + 220 - - +
2 J.E. OvCa Stage Ia - + + 833 - +
recurrent
3 N.N. Stomach Ca Active - - 250 - - +
disease
4 S.L. OvCa Stage III Ag Neg - - 550 - +
tumour
5 W.S. OvCa Stage I NED - - 500 - NT
6 M.D. OvCa Stage IlIc Active - - 765 - + +
disease
7 P.H. Breast Active - - 765 - - +
disease
HAMA: human antimouse murine antibodies; DOTA: 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid; NT:
nottested; HSA: humanserumalbumin; ELISA: enzymelinkedimmunosorbentassay;PLAP: placentalalkalinephosphatase;
2IT: 2 iminothiolane hydrochloride; OvCa: ovarian carcinoma; NED: no evidence of disease.
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